On November 7, 2018 RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (sd-rxRNA) therapeutic platform, reported that it will present a poster highlighting data demonstrating the potential of sd-rxRNA to improve NK cell potency in adoptive cell transfer (ACT) at SITC (Free SITC Whitepaper) 2018, the 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) (Press release, RXi Pharmaceuticals, NOV 7, 2018, View Source [SID1234531026]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The poster, titled "sd-rxRNA to Enhance NK Cell Activity for Adoptive Cell Transfer" (Poster #P258), will be available for viewing from 12:20–1:50 p.m. ET and 7:00–8:30 p.m. ET on Saturday, November 10, 2018.

The poster will also be available under the "Investors – Events and Presentations" section of the Company’s website, View Source, approximately one hour following the presentation.

SITC 2018 is being held November 7-11, 2018 at the Walter E. Washington Convention Center in Washington, DC.